Brolucizumab-Dbll vs CKD-701

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Age-Related Macular Degenerationantibody fragment (scFv)
Weak signal

NCT05672979 · Phase 3 · status unknown

This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.

No aligned efficacy figure on record for this race.

CKD-701 · Lucenbies

Marketed by Chong Kun Dang Pharmaceutical

Phase 3 in Age-Related Macular Degenerationmonoclonal antibody
Reliable signal

NCT04857177 · Phase 3 · completed

In this randomized, double-blind, active-controlled Phase 3 trial, 312 patients with wet AMD were randomized to CKD-701 or the reference biologic Lucentis (ranibizumab). The proportion of patients avoiding significant vision loss was nearly identical between groups (97.95% vs 98.62%), and the difference fell entirely within the trial's prespecified equivalence margin.

Reported efficacy

The proportion of patients with a decrease in the best-corrected visual acuity (BCVA) score of 15 or fewer letters at 3 months versus baseline. (Baseline to 3 months): Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%). (met)

Result source: NCT04857177

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Brolucizumab-Dbll: registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

CKD-701

BCVA Loss Less Than 15 Letters 97.95% vs 98.62% ranibizumab/Lucentis @ 12.99wk
responder rate · % of participants
NCT04857177 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brolucizumab-Dbll's landscape · CKD-701's landscape